Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01999556 |
| Other study ID # |
LCI-HEM-SPEC-001 |
| Secondary ID |
00008179 |
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
November 2013 |
| Est. completion date |
December 22, 2016 |
Study information
| Verified date |
November 2021 |
| Source |
Wake Forest University Health Sciences |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The purpose of this study is to obtain high quality specimens for molecular studies for the
identification and characterization of genetic mutations involved in the pathogenesis of
familial myeloid malignancies. Specimens obtained will be de-identified, linked to basic
clinical data, and sent to Washington University (Division of Oncology, St. Louis, MO) for
molecular analyses. Some specimens sent to Washington University may also be used for quality
control analyses.
Description:
This is a specimen collection study for patients receiving standard of care treatment for
AML. Specimens collected will be 1) bone marrow biopsy and aspiration, 2) peripheral blood,
3) skin punch biopsy, and 4) oral rinse. Collection of these specimens will be at timepoints
determined by the patient's standard of care and their physician Investigator.
